Imoxat

Country: European Union

Language: Latvian

Source: EMA (European Medicines Agency)

Active ingredient:

imidakloprīdu, moksidektīns

Available from:

Chanelle Pharmaceuticals Manufacturing Ltd

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Cats; Dogs; Ferrets

Therapeutic area:

Antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins

Therapeutic indications:

For cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (Ctenocephalides felis),• the treatment of ear mite infestation (Otodectes cynotis),• the treatment of notoedric mange (Notoedres cati),• the treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults),• the prevention of lungworm disease (L3/L4 larvae of Aelurostrongylus abstrusus),• the treatment of the lungworm Aelurostrongylus abstrusus (adults),• the treatment of the eye worm Thelazia callipaeda (adults),• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme). Šīs veterinārās zāles var izmantot kā daļu no blusu alerģiskā dermatīta (FAD) terapijas stratēģijas..  For ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (Ctenocephalides felis),• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).  For dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (Ctenocephalides felis),• the treatment of biting lice (Trichodectes canis),• the treatment of ear mite infestation (Otodectes cynotis), sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis),• the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis),• the treatment of circulating microfilariae (Dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of Dirofilaria repens)• the prevention of cutaneous dirofilariosis (L3 larvae of Dirofilaria repens),• the reduction of circulating microfilariae (Dirofilaria repens),• the prevention of angiostrongylosis (L4 larvae and immature adults of Angiostrongylus vasorum),• the treatment of Angiostrongylus vasorum and Crenosoma vulpis,• the prevention of spirocercosis (Spirocerca lupi),• the treatment of Eucoleus (syn. Capillaria) boehmi (adults),• the treatment of the eye worm Thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis). Šīs veterinārās zāles var izmantot kā daļu no blusu alerģiskā dermatīta (FAD) terapijas stratēģijas..

Authorization status:

Autorizēts

Authorization date:

2021-12-07

Patient Information leaflet

                                48
B. LIETOŠANAS INSTRUKCIJA
49
LIETOŠANAS INSTRUKCIJA
IMOXAT 40 MG + 4 MG ŠĶĪDUMS PILINĀŠANAI UZ ĀDAS MAZA AUGUMA
KAĶIEM UN MĀJAS SESKIEM
IMOXAT 80 MG + 8 MG ŠĶĪDUMS PILINĀŠANAI UZ ĀDAS LIELA AUGUMA
KAĶIEM
1.
REĢISTRĀCIJAS APLIECĪBAS ĪPAŠNIEKA UN RAŽOŠANAS LICENCES
TURĒTĀJA, KURŠ ATBILD PAR SĒRIJAS IZLAIDI, NOSAUKUMS UN ADRESE, JA
DAŽĀDI
Reģistrācijas apliecības īpašnieks un par sērijas izlaidi
atbildīgais ražotājs:
Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea, Co. Galway,
Īrija
2.
VETERINĀRO ZĀĻU NOSAUKUMS
Imoxat 40 mg + 4 mg šķīdums pilināšanai uz ādas maza auguma
kaķiem un mājas seskiem
Imoxat 80 mg + 8 mg šķīdums pilināšanai uz ādas liela auguma
kaķiem
_Imidacloprid, moxidectin _
3.
AKTĪVO VIELU UN CITU VIELU NOSAUKUMS
Katra deva (pipete) satur:
DEVA PIPETĒ
IMIDAKLOPRĪDS
MOKSIDEKTĪNS
Imoxat maza auguma kaķiem (≤ 4 kg) un mājas
seskiem
0,4 ml
40 mg
4 mg
Imoxat liela auguma kaķiem (> 4–8 kg)
0,8 ml
80 mg
8 mg
Palīgvielas: benzilspirts, 1 mg/ml butilhidroksitoluols (E321).
Bezkrāsains līdz dzeltens šķīdums.
4.
INDIKĀCIJA(-S)
KAĶIEM,
kuriem ir jauktas parazitāras invāzijas vai pastāv risks
invadēties:
•
blusu (
_Ctenocephalides felis_
) invāzijas ārstēšanai un kontrolei;
•
ausu kašķa ērču (
_Otodectes cynotis_
) invāzijas ārstēšanai;
•
_Notoedres_
ģints ērču (
_Notoedres cati_
) invāzijas ārstēšanai;
•
plaušu tārpu
_Eucoleus aerophilus _
(sin.
_Capillaria aerophila_
) (pieauguši īpatņi) invāzijas
ārstēšanai;
•
plaušu tārpu (
_Aelurostrongylus abstrusus _
kāpuru L3/L4 stadija) invāzijas kontrolei;
•
plaušu tārpu
_Aelurostrongylus abstrusus _
(pieauguši īpatņi) invāzijas ārstēšanai;
•
acu tārpu
_Thelazia callipaeda _
(pieauguši īpatņi) invāzijas ārstēšanai;
•
sirdstārpu (
_Dirofilaria immitis _
kāpuru L3 un L4 stadija) invāzijas kontrolei;
•
gremošanas trakta nematožu (
_Toxocara cati _
un
_Ancylostoma tubaeforme _
L4 kāpuru stadija,
nenobrieduši pieaug
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
_ _
I PIELIKUMS
VETERINĀRO ZĀĻU APRAKSTS
2
1.
VETERINĀRO ZĀĻU NOSAUKUMS
Imoxat 40 mg + 4 mg šķīdums pilināšanai uz ādas maza auguma
kaķiem un mājas seskiem
Imoxat 80 mg + 8 mg šķīdums pilināšanai uz ādas liela auguma
kaķiem
2.
KVALITATĪVAIS UN KVANTITATĪVAIS SASTĀVS
AKTĪVĀS VIELAS:
Imoxat maza un liela auguma kaķiem un mājas seskiem satur
imidakloprīdu 100 mg/ml un
moksidektīnu 10 mg/ml.
Katra deva (pipete) satur:
DEVA PIPETĒ
IMIDAKLOPRĪDS
MOKSIDEKTĪNS
Imoxat maza auguma kaķiem (≤ 4 kg) un mājas
seskiem
0,4 ml
40 mg
4 mg
Imoxat liela auguma kaķiem (> 4–8 kg)
0,8 ml
80 mg
8 mg
PALĪGVIELAS:
Benzilspirts
Butilhidroksitoluols 1 mg/ml (E321).
Pilnu palīgvielu sarakstu skatīt 6.1. apakšpunktā.
3.
ZĀĻU FORMA
Šķīdums pilināšanai uz ādas.
Bezkrāsains līdz dzeltens šķīdums.
4.
KLĪNISKĀ INFORMĀCIJA
4.1
MĒRĶA SUGAS
Kaķi, mājas seski.
4.2
LIETOŠANAS INDIKĀCIJAS, NORĀDOT MĒRĶA SUGAS
KAĶIEM,
kuriem ir jauktas parazitāras invāzijas vai pastāv risks
invadēties:
•
blusu (
_Ctenocephalides felis_
) invāzijas ārstēšanai un kontrolei;
•
ausu kašķa ērču (
_Otodectes cynotis_
) invāzijas ārstēšanai;
•
_Notoedres_
ģints ērču (
_Notoedres cati_
) invāzijas ārstēšanai;
•
plaušu tārpu
_Eucoleus aerophilus _
(sin.
_Capillaria aerophila_
) (pieauguši īpatņi) invāzijas
ārstēšanai;
•
plaušu tārpu (
_Aelurostrongylus abstrusus _
kāpuru L3/L4 stadija) invāzijas kontrolei;
•
plaušu tārpu
_Aelurostrongylus abstrusus _
(pieauguši īpatņi) invāzijas ārstēšanai;
•
acu tārpu
_Thelazia callipaeda _
(pieauguši īpatņi) invāzijas ārstēšanai;
•
sirdstārpu (
_Dirofilaria immitis _
kāpuru L3 un L4 stadija) invāzijas kontrolei;
•
gremošanas trakta nematožu (
_Toxocara cati _
un
_Ancylostoma tubaeforme _
L4 kāpuru stadija,
nenobrieduši pieauguši īpatņi un pieauguši īpatņi) invāzijas
ārstēšanai.
Šīs veterinārās zāles var lietot kā daļu no blusu alerģiskā
dermatīta (BAD) ārstēšanas strat
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-01-2022
Public Assessment Report Public Assessment Report Bulgarian 24-01-2022
Patient Information leaflet Patient Information leaflet Spanish 24-01-2022
Public Assessment Report Public Assessment Report Spanish 24-01-2022
Patient Information leaflet Patient Information leaflet Czech 24-01-2022
Public Assessment Report Public Assessment Report Czech 24-01-2022
Patient Information leaflet Patient Information leaflet Danish 24-01-2022
Public Assessment Report Public Assessment Report Danish 24-01-2022
Patient Information leaflet Patient Information leaflet German 24-01-2022
Public Assessment Report Public Assessment Report German 24-01-2022
Patient Information leaflet Patient Information leaflet Estonian 24-01-2022
Public Assessment Report Public Assessment Report Estonian 24-01-2022
Patient Information leaflet Patient Information leaflet Greek 24-01-2022
Public Assessment Report Public Assessment Report Greek 24-01-2022
Patient Information leaflet Patient Information leaflet English 24-01-2022
Public Assessment Report Public Assessment Report English 24-01-2022
Patient Information leaflet Patient Information leaflet French 24-01-2022
Public Assessment Report Public Assessment Report French 24-01-2022
Patient Information leaflet Patient Information leaflet Italian 24-01-2022
Public Assessment Report Public Assessment Report Italian 24-01-2022
Patient Information leaflet Patient Information leaflet Lithuanian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-01-2022
Public Assessment Report Public Assessment Report Lithuanian 24-01-2022
Patient Information leaflet Patient Information leaflet Hungarian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 24-01-2022
Public Assessment Report Public Assessment Report Hungarian 24-01-2022
Patient Information leaflet Patient Information leaflet Maltese 24-01-2022
Public Assessment Report Public Assessment Report Maltese 24-01-2022
Patient Information leaflet Patient Information leaflet Dutch 24-01-2022
Public Assessment Report Public Assessment Report Dutch 24-01-2022
Patient Information leaflet Patient Information leaflet Polish 24-01-2022
Public Assessment Report Public Assessment Report Polish 24-01-2022
Patient Information leaflet Patient Information leaflet Portuguese 24-01-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 24-01-2022
Public Assessment Report Public Assessment Report Portuguese 24-01-2022
Patient Information leaflet Patient Information leaflet Romanian 24-01-2022
Public Assessment Report Public Assessment Report Romanian 24-01-2022
Patient Information leaflet Patient Information leaflet Slovak 24-01-2022
Public Assessment Report Public Assessment Report Slovak 24-01-2022
Patient Information leaflet Patient Information leaflet Slovenian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 24-01-2022
Public Assessment Report Public Assessment Report Slovenian 24-01-2022
Patient Information leaflet Patient Information leaflet Finnish 24-01-2022
Public Assessment Report Public Assessment Report Finnish 24-01-2022
Patient Information leaflet Patient Information leaflet Swedish 24-01-2022
Public Assessment Report Public Assessment Report Swedish 24-01-2022
Patient Information leaflet Patient Information leaflet Norwegian 24-01-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 24-01-2022
Patient Information leaflet Patient Information leaflet Icelandic 24-01-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 24-01-2022
Patient Information leaflet Patient Information leaflet Croatian 24-01-2022
Public Assessment Report Public Assessment Report Croatian 24-01-2022

View documents history